文献速递湿疹皮炎与荨麻疹

Amlitelimab改善与维持特应性皮炎临床结局评估的研究解读

Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimab.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2025-07-24

STREAM-AD 2b期试验纳入390例中重度特应性皮炎成人患者,Part 1随机接受不同剂量amlitelimab或安慰剂至第24周,Part 2将临床应答者按3:1再随机分为停药或继续治疗至第52周。结果显示所有amlitelimab剂量组第24周COAs较安慰剂显著改善,第52周COAs改善在继续治疗和停药患者中均得以维持。

要点

  • Amlitelimab第24周可显著改善中重度AD患者多项COAs,各剂量组与安慰剂比较p<0.05。
  • 第24周COA改善的临床应答者中,多数在第52周仍维持改善。
  • Part 2期间停药或继续治疗均维持COA改善,支持延长给药间隔可能减轻治疗负担。

核心结论

  • Amlitelimab治疗至第24周使中重度AD患者COAs较安慰剂出现有临床意义的改善。
  • 第52周时,继续或停用amlitelimab的患者中COAs改善均得以维持,支持持久应答和延长给药可行性。

研究设计与样本

  • STREAM-AD为随机2b期试验,Part 1纳入390例中重度AD成人患者,按1:1:1:1:1随机接受皮下amlitelimab(250 mg伴500 mg负荷剂量、250 mg、125 mg或62.5 mg)或安慰剂每4周一次至第24周。
  • Part 2将第24周临床应答者(IGA 0/1和/或EASI-75)按3:1再随机分为停药或继续原剂量至第52周,共190例再随机。

主要发现

  • 第24周所有amlitelimab剂量组COAs较安慰剂显著改善(所有COAs p<0.05)。
  • 第24周多数临床应答者达到COAs的有意义变化。
  • 第52周时,第24周达到COA改善的多数患者维持改善,与Part 2期间继续或停药无关。

关键数值与推荐

  • 临床应答定义为IGA 0/1和/或EASI-75。
  • 评估的COAs包括SCORing Atopic Dermatitis、受累体表面积、Patient-Oriented Eczema Measure、Dermatology Life Quality Index和Atopic Dermatitis Control Tool。

临床怎么用

  • Amlitelimab可用于中重度AD患者,第24周起可观察到多项患者报告和临床评估结局的改善。
  • 第52周COA改善在停药后仍维持,提示可考虑延长给药间隔以减轻治疗负担。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Amlitelimab, a fully human, nondepleting, anti-OX40 ligand monoclonal antibody, demonstrated reductions in lesional and pruritic endpoints in adults with moderate-to-severe atopic dermatitis (AD) in phase 2a and 2b trials. OBJECTIVES: Here, we examined the effect and durability of amlitelimab on clinical outcome assessments (COAs) in the randomized STREAM-AD phase 2b trial. METHODS: Adults with moderate-to-severe AD with prior inadequate response to or inadvisability of topical medications received subcutaneous amlitelimab (250 mg with 500-mg loading dose, 250 mg, 125 mg or 62.5 mg) or placebo every 4 weeks in Part 1 (Weeks 0-24; 1:1:1:1:1 randomization). In Part 2, Week 24 clinical responders (defined as patients achieving Investigator Global Assessment [IGA] 0/1 and/or ≥ 75% reduction in the Eczema Area and Severity Index [EASI-75]) were rerandomized 3:1 to withdraw or continue amlitelimab pre-Week 24 dose through Week 52. COAs, including SCORing Atopic Dermatitis, affected body surface area, Patient-Oriented Eczema Measure, Dermatology Life Quality Index and Atopic Dermatitis Control Tool, were evaluated. RESULTS: Of the 390 randomized patients in Part 1, 190 were rerandomized in Part 2. Significant improvements in COAs were observed with all amlitelimab doses versus placebo at Week 24 (p < 0.05 for all COAs). At Week 24, the majority of clinical responders achieved meaningful changes in COAs. At Week 52, these improvements were maintained in the majority of patients who achieved COA improvements at Week 24, regardless of treatment continuation or withdrawal during the 28-week Part 2 period. CONCLUSIONS: Amlitelimab treatment led to clinically meaningful improvements in COAs by Week 24 versus placebo. COA improvements were maintained at Week 52 in patients continuing amlitelimab, as well as in patients who withdrew from amlitelimab, supporting the durable response of amlitelimab and the viability of extended drug dosing, which may ease treatment burden. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05131477.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Blauvelt A, Chovatiya R, Merola JF, et al. Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimab. J Eur Acad Dermatol Venereol. 2025. PMID: 40704660. doi:10.1111/jdv.20877

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。